ATE365542T1 - Lyophilisierbare pharmazeutische plazebozusammensetzung , insbesondere auf basis von proteinen oder polypeptiden, zur nachahmung eines arzneimittels - Google Patents

Lyophilisierbare pharmazeutische plazebozusammensetzung , insbesondere auf basis von proteinen oder polypeptiden, zur nachahmung eines arzneimittels

Info

Publication number
ATE365542T1
ATE365542T1 AT98943975T AT98943975T ATE365542T1 AT E365542 T1 ATE365542 T1 AT E365542T1 AT 98943975 T AT98943975 T AT 98943975T AT 98943975 T AT98943975 T AT 98943975T AT E365542 T1 ATE365542 T1 AT E365542T1
Authority
AT
Austria
Prior art keywords
medicinal product
proteins
imimate
lyophilizable
polypeptides
Prior art date
Application number
AT98943975T
Other languages
English (en)
Inventor
Annie Bardat
Roland Schmitthauesler
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Application granted granted Critical
Publication of ATE365542T1 publication Critical patent/ATE365542T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT98943975T 1997-09-18 1998-09-14 Lyophilisierbare pharmazeutische plazebozusammensetzung , insbesondere auf basis von proteinen oder polypeptiden, zur nachahmung eines arzneimittels ATE365542T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9711626A FR2768341B1 (fr) 1997-09-18 1997-09-18 Composition pharmaceutique placebo lyophilisable destinee a imiter un medicament, notamment a base de proteines ou de polypeptides

Publications (1)

Publication Number Publication Date
ATE365542T1 true ATE365542T1 (de) 2007-07-15

Family

ID=9511216

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98943975T ATE365542T1 (de) 1997-09-18 1998-09-14 Lyophilisierbare pharmazeutische plazebozusammensetzung , insbesondere auf basis von proteinen oder polypeptiden, zur nachahmung eines arzneimittels

Country Status (11)

Country Link
US (1) US6242423B1 (de)
EP (1) EP1014948B1 (de)
AT (1) ATE365542T1 (de)
CA (1) CA2304021A1 (de)
CY (1) CY1106769T1 (de)
DE (1) DE69837997T2 (de)
DK (1) DK1014948T3 (de)
ES (1) ES2287980T3 (de)
FR (1) FR2768341B1 (de)
PT (1) PT1014948E (de)
WO (1) WO1999013866A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2768341B1 (fr) * 1997-09-18 2000-04-14 Lab Francais Du Fractionnement Composition pharmaceutique placebo lyophilisable destinee a imiter un medicament, notamment a base de proteines ou de polypeptides
US6566575B1 (en) 2000-02-15 2003-05-20 3M Innovative Properties Company Patterned absorbent article for wound dressing
US6977323B1 (en) 2000-02-17 2005-12-20 3M Innovative Properties Company Foam-on-film medical articles
US6716186B1 (en) 2000-08-16 2004-04-06 3M Innovative Properties Company Curable adhesive splints and methods
US6903243B1 (en) 2000-09-08 2005-06-07 3M Innovative Properties Company Multi-layer absorbent wound dressing
US7005143B2 (en) 2002-04-12 2006-02-28 3M Innovative Properties Company Gel materials, medical articles, and methods
US7612248B2 (en) 2002-12-19 2009-11-03 3M Innovative Properties Company Absorbent medical articles
US20050070688A1 (en) 2003-09-26 2005-03-31 3M Innovative Properties Company Reactive hydrophilic oligomers
US7384984B2 (en) 2003-12-10 2008-06-10 3M Innovative Properties Company Reactive hydrophilic oligomers
US7074839B2 (en) * 2004-03-01 2006-07-11 3M Innovative Properties Company Crosslinkable hydrophilic materials from reactive oligomers having pendent photoinitiator groups
US7342047B2 (en) 2004-03-02 2008-03-11 3M Innovative Properties Company Crosslinkable hydrophilic materials from reactive oligomers having pendent unsaturated groups
US7335690B2 (en) 2005-01-25 2008-02-26 3M Innovative Properties Company Crosslinkable hydrophilic materials from polymers having pendent Michael donor groups
US8609131B2 (en) 2005-01-25 2013-12-17 3M Innovative Properties Company Absorbent dressing comprising hydrophilic polymer prepared via Michael reaction
US7981949B2 (en) 2006-05-23 2011-07-19 3M Innovative Properties Company Curable hydrophilic compositions
US20110155620A1 (en) 2009-12-30 2011-06-30 Baxter International Inc. Rapid reconstitution for lyophilized-pharmaceutical suspensions
WO2023183542A2 (en) * 2022-03-25 2023-09-28 Amgen Inc. Artificial lyophilized product samples for automated visual inspection systems

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5151511A (en) * 1974-10-25 1976-05-07 Tooru Tatsuhara Aminosanseizai no anteikaho
ATE24964T1 (de) * 1981-12-11 1987-01-15 Wyeth John & Brother Ltd Verfahren zur herstellung von festen formgegenstaenden.
IL78930A0 (en) * 1985-07-29 1986-09-30 Abbott Lab Lyophilized emulsion compositions for parenteral administration
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
FR2751177B1 (fr) * 1996-07-17 1998-08-28 Morelle Jean Compositions exemptes de proteines et de peptides obtenues a partir de toutes proteines animales, destinees a l'alimentation animale et humaine, ainsi qu'a l'usage cosmetique pharmaceutique et agricole
FR2768341B1 (fr) * 1997-09-18 2000-04-14 Lab Francais Du Fractionnement Composition pharmaceutique placebo lyophilisable destinee a imiter un medicament, notamment a base de proteines ou de polypeptides

Also Published As

Publication number Publication date
WO1999013866A1 (fr) 1999-03-25
CY1106769T1 (el) 2012-05-23
US6242423B1 (en) 2001-06-05
PT1014948E (pt) 2007-07-18
EP1014948A1 (de) 2000-07-05
FR2768341B1 (fr) 2000-04-14
DE69837997T2 (de) 2008-02-28
FR2768341A1 (fr) 1999-03-19
DK1014948T3 (da) 2007-09-24
DE69837997D1 (de) 2007-08-09
CA2304021A1 (fr) 1999-03-25
ES2287980T3 (es) 2007-12-16
EP1014948B1 (de) 2007-06-27

Similar Documents

Publication Publication Date Title
ATE365542T1 (de) Lyophilisierbare pharmazeutische plazebozusammensetzung , insbesondere auf basis von proteinen oder polypeptiden, zur nachahmung eines arzneimittels
AU6819294A (en) Oral drug delivery compositions and methods
KR920019371A (ko) 안정화된 인자 ⅷ 제제
MX9207334A (es) Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene
ATE75945T1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
WO2000012542A3 (en) Cytotoxic lactoferrin derivatives modified by bulky or lipophilic moieties
ATE187740T1 (de) Modifizierte proteine und peptide enthaltende pharmazeutische mittel
PT96016A (pt) Processo para a preparacao de uma composicao farmaceutica para a aplicacao subcutanea ou intramuscular contendo polipeptidos
MX9703642A (es) Metodos para el tratamiento de esclerosis multiple utilizando analogos de peptido en la posicion 91 de la proteina basica de mielina humana.
BR9811755A (pt) Peptìdeo, processo para o tratamento da obesidade em um animal, uso de um peptìdeo, e, composição farmacêutica
BR0116122A (pt) Peptìdeos e/ou proteìnas bem como seu uso para preparar uma composição farmacêutica, terapêutica e/ou preventiva
KR900701832A (ko) 항-트롬빈
BR9809103A (pt) Forma farmacêutica estável de administração para peptìdeos, proteìnas e ácidos nucléicos
ATE392428T1 (de) Arzneimittel enthaltend analgetische peptide
ATE211765T1 (de) Neue familie von proteaseinhibitoren und andere biologisch aktive substanzen
GB9311454D0 (en) Pharmaceutical compositions
ATE3416T1 (de) Pharmakologisch aktive peptide und diese enthaltende arzneimittel.
KR910700259A (ko) T-세포 인지성 펩티드 변형에 의해 면역반응에 영향을 주는 방법
ATE93527T1 (de) Peptide und deren benutzung.
FI942938A (fi) Soijaproteiini tai -hydrolysaatit farmaseuttisissa koostumuksissa bioaktiivisten peptidien suojana entsymaattista inaktivoitumista vastaan
DE59409413D1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
KR930004326A (ko) 콘드로모듈린-ii 단백질
BR0113579A (pt) Proteìnas sintéticas modificadas por polìmero
HK1029277A1 (en) Pharmaceutical coating composition and method of use.
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1014948

Country of ref document: EP